Antiphospholipid syndrome by Clark, KEN & Giles, I
Antiphospholipid Syndrome 
Kristina E. N. Clark, Specialist Registrar in rheumatology at University College London, 
London, United Kingdom. 
 
Competing interests: none declared 
 
Kristina EN Clark BA/MBBS MRCP is a Specialist Trainee in Rheumatology at the University 
College London Hospitals, UK 
 
Ian Giles Reader in Rheumatology at University College London, London, United Kingdom.  
 
Competing interests: none declared. 
 
Ian Giles PhD FRCP is a Reader in Rheumatology at UCL and Honorary Consultant at 
University College London Hospitals, UK, with a specialist interest in antiphospholipid 
syndrome and pregnancy outcomes in rheumatic disease 
 
Corresponding author 
Dr Ian Giles 
Department of Rheumatology 
UCLH 
3rd Floor Central 
250 Euston Road 













Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia characterised 
by venous or arterial thrombosis, and/or pregnancy loss or complications in the presence of 
persistently positive antiphospholipid antibodies (aPL). Patients can also develop other 
organ involvement, referred to as non-criteria manifestations including livedo reticularis, 
thrombocytopaenia and nephropathy. Increasingly, non-thrombotic inflammatory 
mechanisms are identified in APS pathogenesis along with recognition that obstetric APS 
may be a specific subset of APS. Treatment remains focused on lifelong anticoagulation, and 
prevention of further thrombosis/ obstetric complications. Identification however, of novel 
mechanisms are leading development of diagnostic tests and more targeted therapies to 
improve management of this disease.  
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Introduction 
Clinical manifestations of venous or arterial thrombosis and/or certain forms of pregnancy 
loss in the presence of persistently positive antiphospholipid antibodies (aPL) are required 
to classify (1) antiphospholipid syndrome (APS) according to international criteria (Table 1). 
These criteria, primarily intended to create well defined cohorts for research studies, are 
routinely applied in clinical practice to aid diagnosis. Current criteria aPL tests include 
detection of: anti-cardiolipin antibodies (aCL) and/or anti-β2-glycoprotein I (β2GPI) 
antibodies by enzyme linked immunosorbent assay (ELISA); and/or positive lupus 
anticoagulant (LA) assay by prolongation of in vitro phospholipid (PL) dependent clotting 
assays that can be corrected by addition of excess PL.  
 
Epidemiology 
Estimates of aPL in the general population vary around 1-5% and their prevalence is 
increased in: the elderly; various medications; infections (including human 
immunodeficiency virus, varicella, hepatitis C, syphilis, malaria and leprosy); 
lymphoproliferative disorders; and other autoimmune rheumatic diseases (ARD), principally 
systemic lupus erythematosus (SLE). The precise prevalence of APS however is unknown. 
The APS Alliance for Clinical Trials and International Networking (APS ACTION) systematically 
analysed published studies to produce estimates of aPL prevalence of: 6% in pregnancy 
morbidity; 10% in deep vein thrombosis (DVT); 11% in myocardial infarction; 14% in stroke; 
and 17% in stroke in individuals less than 50 years. 
 
An observational European study (Euro-Phospholipid project) has defined the characteristics 
of 1000 patients with APS (2). Of these patients 82% were female and the majority (53.1%) 
had primary APS in the absence of another disease and the remainder had APS in 
association with another ARD, most commonly SLE. Although these cases were originally 
defined as secondary APS this distinction is now considered less useful and current 
classification criteria recommend any associated disorder be reported as ARD associated 
APS. Although, aPL are found in up to 40% of patients with SLE only 40% of those patients 
will develop APS. A more severe variant with widespread microvascular thrombosis and high 
morbidity/mortality, known as Catastrophic (C)APS occurs in 1% of patients with APS.  
 
Pathogenesis 
Animal models and in vitro studies provide direct evidence that aPL cause thrombotic and 
obstetric APS manifestations (3). One of the main distinguishing properties of pathogenic 
aPL is their binding to β2GPI, a protein composed of five regions called domains (D)I to V 
that contains an important epitope for pathogenic aPL on DI, particularly the region from 
arginine (Arg)39 to Arg43. Other antibodies have been identified in APS including those 
directed against prothrombin, protein C, protein S, Annexin V and Factor Xa. Interestingly, 
antibodies directed against β2GPI and prothrombin have shown to be responsible for 
prolongation of clotting times observed in vitro in LA tests.  In contrast to this in vitro 
anticoagulant phenomenon, pathogenic aPL have been shown to have inflammatory, 
thrombotic and adverse obstetric effects in various animal models and upon various target 
cells including: monocytes, endothelial cells, neutrophils and trophoblast cells, leading to 
the recruitment of cell surface receptors, perturbation of intracellular signalling pathways 
and upregulation of pro-inflammatory and pro-coagulant factors. These effects are 
mediated through interactions with components of the coagulation and/or complement 
cascade as well as cell surface interactions between aPL-β2GPI complexes cross-linking 
various receptors on different cell types (Figure 1).  
 
A “two-hit” hypothesis has been proposed, whereby the first hit is an aPL induced pro-
thrombotic/inflammatory state and the second is exposure to an acute precipitating event 
such as surgery, immobilisation, exogenous oestrogen or pregnancy. Interestingly, 
pregnancy does not serve purely as a precipitating pro-thrombotic state, since comparison 
of products of conception from aPL-positive and negative patients with recurrent early 
miscarriage demonstrates a specific defect in decidual endovascular trophoblast invasion in 
obstetric (O)APS and that placental infarction is not unique to APS. Increasingly, 
experimental evidence implicates non-thrombotic mechanisms in the pathogenesis of OAPS 
by aPL mediated complement activation, inflammation as well as impairment of placental 
development and function (Figure 1). In addition, clinical data from the European registry on 
Obstetric APS (EUROAPS) on 247 patients with OAPS demonstrated that progression to 
thrombosis and SLE are scarce compared with patients with thrombotic APS (4), thus 
lending credence to the hypothesis that OAPS is a specific subset with APS. 
 
Clinical features 
Although vascular thrombosis and certain adverse pregnancy outcomes remain are the main 
clinical features of APS other non-classification criteria clinical features are increasingly 
recognised (Table 2) and indicate the variety of non-thrombotic effects of aPL. For instance, 
in the Euro-Phospholipid project the most common presenting non-criteria features were 
thrombocytopenia (21.9%), livedo reticularis (20.4%), superficial thrombophlebitis (9.1%), 
and haemolytic anaemia (6.6%).  
 
Vascular thrombosis 
Thrombotic events are the hallmark of APS, most commonly venous events in the lower 
limbs. The presence of aPL increases the risk of venous thrombosis in patients with SLE two-
fold for aCL and six-fold for LA, compared to normal populations. In patients without an 
underlying ARD, venous thrombotic risk is increased 1.5-fold for aCL and up to 10-fold for 
LA, whilst arterial thrombosis is increased three (aCL) and four (LA) - fold. The risk of 
recurrent thrombosis or thromboembolism may be further enhanced in patients with triple 
positivity to LA, aCL and anti- β2GPI antibodies. Vascular events in the Euro-Phospholipid 
project included DVT (32%), stroke (13.1%), pulmonary embolism – PE - (9.0%), transient 
ischaemic attack (7.0%) and amaurosis fugax (2.8%). Given that aPL positivity is found in 
17% of strokes in patients less than 50 years of age (compared with 0.7% of controls), the 
British Society of Haematology guidelines on investigation and management of APS 
recommends that anyone presenting with an ischaemic stroke under the age of 50 be 
screened for aPL (5).  
 
Obstetric manifestations 
The current classification of obstetric APS is shown in Table 1. Recurrent miscarriages are a 
hallmark of APS. In the Euro-Phospholipid project the most common fetal complications 
were early fetal loss (35.4%), late fetal loss (16.9%), and premature birth (10.6% of live 
births). The most common obstetric complications in the mother were preeclampsia (9.5% 
of pregnant women), eclampsia (4.4%), and abruptio placentae (2.0%). Similarly, recurrent 
miscarriage and late fetal loss were the commonest complications in the EUROAPS registry. 
Whilst, laboratory data from the Euro-phospholipid and EUROAPS series confirm 
associations between all criteria aPL and pregnancy complications, the strongest association 
was found with LA and triple positivity.    
 
Non-Criteria Manifestations 
Although many of the multisystem manifestations of APS (Table 2) are thrombotic in nature, 
it is increasingly recognised that aPL have other immune mediated effects that give rise to 
manifestations that fall outside of current APS classification criteria.  These non-criteria 
manifestations involve multiple organ systems. Patients may present with valvular heart 
disease, and develop a sterile endocarditis (Libman-Sacks endocarditis) that give rise to 
embolic complications. Livedo reticularis is the most common dermatological manifestation 
of APS and when associated with aPL and stroke is known as Sneddon syndrome; less 
commonly skin ulceration may occur. Other non-ischaemic neurologic complications include 
chorea, psychiatric disorders, Guillain-Barre syndrome, transverse myelopathy, dementia 
and seizures.  Thrombocytopaenia is a common finding on laboratory investigations, as is a 
prolonged aactivated Partial Thromboplastin Time (aPTT), yet bruising is rarely seen. An APS 
nephropathy has been described in which aPL cause renal endothelial intimal hyperplasia 
independently of thrombosis due to activation of the mammalian target of rapamycin 
(mTOR) pathway.   
 
Catastrophic antiphospholipid syndrome (CAPS) 
CAPS is a rare form of APS with high mortality presenting as a microangiopathic storm in the 
presence of aPL with no other likely diagnosis. Classification criteria have been developed 
and require presence of aPL, rapid onset of microthrombii in three or more organs within a 
week, biopsy confirmation of microthrombii and exclusion of other causes. In 65% of cases 
there is a precipitating cause such as infection, a surgical procedure or cessation of 
anticoagulation. It typically presents with multi-organ failure of kidneys, lungs, bowel, heart 
and brain. Mortality is high (44%) without treatment.  
 
Seronegative APS 
The occurrence of typical thrombotic or obstetric manifestations satisfying APS classification 
criteria in patients who are persistently negative for criteria aPL and lack any other 
identifiable cause has led to the concept of seronegative APS. This concept has not been as 
readily accepted as in other ARD, such as seronegative rheumatoid arthritis, but may be 
explained by a problem with sensitivity of current criteria tests rather than inaccurate 
diagnosis and has led to a search for other non-criteria aPL. A recent cohort study of 40 
patients with seronegative APS, found 10% of patients to be positive for one or more non-
criteria aPL, including anti-DI IgG and IgA aCL.  
 
Diagnosis  
The diagnosis of APs should be considered in the presence of otherwise unexplained: one or 
more thrombotic events; one or more specific adverse pregnancy events; thrombocytopenia 
or prolongation of clotting assay. Antibody testing for aPL should then be performed in 
these patients. Diagnosis is usually made according to classification criteria (Table 1) and 
based on the presence of one or both major clinical (thrombotic or obstetric) manifestations 
and persistent positivity of criteria aPL. It is important to recognise however, that these 
classification criteria are primarily a research tool that are currently undergoing revision and 
may alter in future iterations. Therefore, although they are routinely used to diagnose APS, 
consideration of this diagnosis may be made in certain patients who do not fulfil these 
criteria, such as individuals with otherwise unexplained thrombocytopenia, heart valve 
disease, renal thrombotic microangiopathy, or those with aPL-related clinical events and 
borderline positive aPL testing. In these circumstances however, consultation with a 




Current criteria aPL tests consist of two direct ELISAs that detect antibodies against CL or 
β2GPI and the LA assay. Interpretation of the LA test is often challenging and a true positive 
result requires positivity in two clotting assays one of which must be the Factor Xa 
dependent dilute Russell Venom Viper Time (dRVVT) and one other, commonly the aPTT. 
The diagnosis of APS requires persistently positive (on at least two occasions, 12 or more 
weeks apart) IgG/M aCL and/or IgG/M anti-β2GPI and/or LA tests. There are no data to 
validate this time interval but it is designed to avoid inclusion of transiently positive (non-
pathogenic) aPL that may arise due to infections and are not typically associated with the 
clinical features of APS. 
  
Further investigations are required to exclude other associated conditions or causes of 
thrombotic/obstetric manifestations (Table 3). Standard blood tests are useful to examine 
for complications, coexistent ARD and alternative causes of positive aPL including infections, 
medications, malignancy as well as other coagulopathies. Thrombocytopaenia is a frequent 
finding in APS. Raised inflammatory markers, such as ESR may indicate co-existing 
inflammatory disease. Renal function is required, with a protein to creatinine ratio to 
exclude renal involvement. Immunology tests include ANA, ENA, C3/C4 and anti-dsDNA 
antibodies are important to examine for associated ARD, particularly SLE. A thrombophilia 
screen may be appropriate to exclude other coagulopathies if the findings will alter 
management as well as evaluation of other risk factors for thrombosis and/or pregnancy 
morbidity. 
  
Imaging     
If respiratory symptoms are the predominant feature, then a chest x-ray is required, 
followed by a ventilation-perfusion scan or a CT pulmonary angiogram to exclude a 
pulmonary embolus. If neurological deficits are apparent then imaging of the brain is 




An ECG may display left ventricular hypertrophy in acute or chronic PE. Echocardiography 
may be required to detect heart valve lesions. 
  
Histology 
Histopathological confirmation is rarely required in primary APS but may be helpful if there 
is diagnostic uncertainty with manifestations. A typical finding in APS is thrombosis without 
evidence of inflammation in the vessel wall. Renal biopsies in renal APS carry a high 
mortality and are rarely indicated unless there is uncertainty as to aetiology of renal 
impairment, such as in SLE/APS. In patients with primary APS, vasculo-occlussive lesions in 
small renal vessels may cause fibrous intimal hyperplasia and thrombotic microangiopathy.  
 
Non-criteria tests 
Problems with performance of criteria assays has led researchers to try and identify other 
aPL that are not recognised in standard criteria tests, by the development of alternative 
“non-criteria” assays. Particular attention has focussed on assays to detect antibodies 
against other PLs (such as phosphatidylethanolamine and phosphatidylserine (PS)); other 
proteins of the coagulation cascade (such as prothrombin (PT) and PS-PT complexes); to 
specific domains (particularly DI) of β2GPI; and a functional assay measuring annexin A5 
resistance. In addition, there is increasing interest in detection of IgA aCL and anti-β2GPI. 
None of these assays however are available or indeed validated for routine clinical use 
(Table 3).    
 
Management 
The management of APS is outlined in Table 4. 
Asymptomatic patients 
The risk of thrombosis in asymptomatic aPL carriers depends upon the type, titre and 
number of different aPL positive. A prospective study following aPL positive patients with no 
previous thrombosis found that the risk of thrombosis if only one aPL antibody is present is 
the same for the general population (0.65% per year). The risk increases to 5.3% per year if 
the patient is triple antibody positive. Although there is no evidence to support routine 
thromboprophylaxis in asymptomatic aPL carriers, other modifiable vascular risk risk factors 
should be actively managed, smoking cessation encouraged and oestrogen containing 
therapies avoided. In transient situations of increased thrombotic risk such as 
hospitalisation or prolonged immobility short term heparin prophylaxis is advisable. 
Evidence is limited in women with asymptomatic aPL and no previous pregnancy morbidity 
and various consensus groups recommend careful monitoring and administration of low-
dose aspirin in pregnancy. In women with coexistent SLE the administration of low aspirin 
has the additional benefit to reduce the risk of pre-eclampsia in pregnancy.  
 
Vascular thrombosis  
Anticoagulation treatment is required lifelong for any patient with persistently positive aPL 
and a history of unprovoked thromboembolism. Anticoagulation is initiated with heparin 
and continued with warfarin. The intensity of anticoagulation has been much debated and 
the current standard of care for long term management of venous thrombosis in APS to 
maintain an INR between 2-3 is based on two randomised controlled trials that found no 
benefit of high intensity (INR >3) compared with low intensity (INR 2-3) warfarin in 
preventing recurrent thrombosis. Given that the recurrence rate and number of arterial 
events was low in these studies, the optimal management of arterial thrombosis in APS 
remains a matter of debate with some experts recommending a combination of warfarin 
(INR of 2-3) with low dose aspirin, whilst others advocate warfarin with higher INR of 3-4. It 
is important to note however, that as the anticoagulant target dose is increased so too is the 
risk of haemorrhage.  
 
The use of direct oral anticoagulants (DOAC) are established as alternatives to VKAs for a 
wide range of indications outside of APS and rivaroxaban (a FXa inhibitor) has been shown 
to be a safe alternative to warfarin in secondary prevention of venous thrombotic APS in the 
Rivaroxaban in APS (RAPS) study. There is no current evidence however, to support use of 
DOACs in arterial thrombosis in APS.  
 
For recurrent thrombosis on warfarin options include: increasing target INR to 3-4 if 
recurrence occurred at INR 2-3; addition of low dose aspirin (or clopidogrel); or switching to 
low molecular weight heparin (LMWH). Other potential adjunctive agents include: 
hydroxychloroquine, with proven anti-inflammatory and anti-thrombotic properties in SLE; 
statins, which have anti-inflammatory properties in small APS cohorts and reduce venous 
thromboembolism in large population cohorts; and sirolimus, an mTOR inhibitor that has 
been shown to reduce renal vasculopathy post-renal transplantation for APS nephropathy. 
Multiple case reports and series have shown benefit of Rituximab in refractory APS and in 
an open-label phase IIa descriptive pilot (RITAPS) study RTX was effective at controlling 
some non-criteria manifestations. Potential alternative and future therapies are outlined in 
Table 5.  
 
Pregnancy 
In patients with previous OAPS only (hence lacking thrombosis) low-dose aspirin and LMWH 
are advised throughout pregnancy. The level of evidence for this therapeutic regime varies 
for different aPL related obstetric manifestations with some studies supporting aspirin 
alone. Overall however, systematic reviews and consensus documents support combination 
with LMWH and aspirin. Where aspirin and heparin are not enough to result in a successful 
term pregnancy, there are few evidence based options. In patients with SLE/APS 
consideration should be given to concomitant treatment with medications to control 
disease activity that are compatible with pregnancy such as steroids and 
hydroxychloroquine. 
 
In patients with thrombotic APS warfarin is not recommended throughout pregnancy 
because of its teratogenic effects on the foetus and should be switched to therapeutic 
heparin at confirmation of pregnancy. Pre-pregnancy counselling is advisable to warn 
patients of pregnancy risks and these therapeutic requirements.   
 
Catastrophic APS   
Management of this rare condition is based on collective experience from the international 
CAPS registry that suggests anticoagulation, high dose intravenous glucocorticoids, 
intravenous immunoglobulin, plasma exchange and cyclophosphamide, particularly in ARD 
associated APS. Rituximab may be considered if patients are not responsive to standard 
therapy and a complement inhibitor eculizumab has shown benefit in case reports.  
 
Prognosis  
The 10 year follow-up data from the Euro-phospholipid project of patients having standard 
treatment for APS revealed a re-thrombosis rate of 15.3%. Although the most common 
presenting thrombotic event was a DVT, arterial thrombotic events increased in incidence 
during the course of the disease. The commonest obstetric complication was early 
pregnancy loss in 16.5%. Despite 72.9% of pregnancies succeeding in having one or more 
live births, there remained a high degree of fetal morbidity (48.2% being premature). A total 
of 9.3% of patients died during the 10-year period, with severe thrombotic events 
accounting for the majority of deaths (myocardial infarction, strokes and PE accounts for 






















1) A 33 year old woman with SLE presents to the acute medical services with a severe 
headache which has been progressively deteriorating over the last 2 days. She takes 
hydroxychloroquine 200 mg BD.  
Her initial observations show a blood pressure of 110/70 and heart rate 80. Shortly after this 
she becomes drowsy and is unable to hold a conversation. There is no obvious focal 
neurological deficit.  
Blood tests show: 
ESR 20mm/hr (0-20)  
WBC 12 x109/L  (4-11) 
Neutrophils 9 x 109/L (2-7.5) 
aPTT 42 seconds (23-31 seconds) 
Liver function tests normal 
C3 0.93 g/L (0.9-1.8)  
CRP 2 mg/L (0-5) 
What is the most appropriate investigation to elicit the diagnosis? 
a) CT angiography of the brain 
b) Blood and urine culture 
c) Lumbar Puncture 
d) CT brain with venogram 
e) CT brain 
 
Answer is d)- due to the prolonged aPTT, the patient likely has secondary antiphospholipid 
syndrome, and has developed a venous sinus thrombosis. 
 
 
2) A 31 year old woman with SLE on hydroxychloroquine attends clinic 7 weeks pregnant. 
She has had one previous pregnancy 3 years ago however this ended with a miscarriage at 
12 weeks, and she is not sure of the cause. She is known to have a persistently positive 
lupus anticoagulant on previous serological testing.  
What are the current guidelines for the management of this patient?  
 a) Unfractionated heparin 
b) Combined low dose aspirin and low molecular weight heparin 
c) Low dose aspirin 
d) Low molecular weight heparin 
e) Hydroxychloroquine and aspirin 
The answer is b) the patient fulfils APS classification criteria, and will require both aspirin 
and LMWH 
 
3) Which of the following is not a criteria aPL test? 
a) IgM anti-β2GPI antibodies 
b) IgG anticardiolipin antibodies 
c) IgG Anti-β2GPI antibodies 
d) IgA anticardiolipin antibodies 
e) dRVVT for lupus anticoagulant 
 


















1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of 
the classification criteria for definite antiphospholipid syndrome (APS). Journal of thrombosis and 
haemostasis : JTH. 2006;4(2):295-306. 
2. Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid 
syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 
2015;74(6):1011-8. 
3. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. The New 
England journal of medicine. 2013;368(11):1033-44. 
4. Alijotas-Reig J, Ferrer-Oliveras R, Ruffatti A, et al. The European Registry on Obstetric 
Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases. Autoimmun Rev. 
2015;14(5):387-95. 
5. Keeling D, Mackie I, Moore GW, et al. Guidelines on the investigation and management of 





1. Andreoli L, Chighizola CB, Banzato A, et al. Estimated Frequency of Antiphospholipid 
Antibodies in Patients With Pregnancy Morbidity, Stroke, Myocardial Infarction, and Deep Vein 
Thrombosis: A Critical Review of the Literature. Arthritis Care & Research. 2013;65(11):1869-73. 
2. Cervera R. CAPS Registry. Lupus. 2012;21(7):755-7. 
3. Cousins L, Pericleous C, Khamashta M, et al. Antibodies to domain I of beta-2-glycoprotein I 
and IgA antiphospholipid antibodies in patients with 'seronegative' antiphospholipid syndrome. Ann 
Rheum Dis. 2015;74(1):317-9. 
4. Abreu MM, Danowski A, Wahl DG, et al. The relevance of "non-criteria" clinical 
manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid 
Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun 
Rev. 2015;14(5):401-14. 
5. Moore GW. Recent guidelines and recommendations for laboratory detection of lupus 
anticoagulants. Semin Thromb Hemost. 2014;40(2):163-71. 
6. Canaud G, Bienaime F, Tabarin F, et al. Inhibition of the mTORC pathway in the 
antiphospholipid syndrome. The New England journal of medicine. 2014;371(4):303-12. 
7. Bertolaccini ML, Amengual O, Andreoli L, et al. 14th International Congress on 
Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory 
diagnostics and trends. Autoimmunity Reviews. 2014;13(9):917-30. 
8. Chighizola CB, Ubiali T, Meroni PL. Treatment of Thrombotic Antiphospholipid Syndrome: 
The Rationale of Current Management-An Insight into Future Approaches. J Immunol Res. 
2015;2015:951424. 
9. Cohen H, Hunt BJ, Efthymiou M, et al. Rivaroxaban versus warfarin to treat patients with 
thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a 
randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 
2016;3(9):e426-36. 
10. de Jesus GR, Agmon-Levin N, Andrade CA, et al. 14th International Congress on 
Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome. 






























Table 1:  Classification Criteria for APS.  
Presence of one feature from both clinical and laboratory criteria is required to fit the 
classification. The classification criteria are primarily a research tool, and do not include all 















• Vascular thrombosis 
– Arterial, venous or small vessel thrombosis in any tissue or organ (excluding superficial 
thrombosis), confirmed by appropriate imaging or histopathology 
• Pregnancy morbidity- at least one of the following 
– One or more unexplained deaths of a morphologically normal foetus at or beyond 10th 
week of gestation 
– One or more premature births or a morphologically normal neonate before 34th week 
of gestation due to eclampsia or severe pre-eclampsia or placental insufficiency 
– Three or more unexplained consecutive spontaneous abortions before 10th week of 
gestation, with hormonal, chromosomal or maternal anatomic causes excluded 
Laboratory Criteria: Any must be present on 2 or more occasions at least 12 weeks apart: 
• Lupus anticoagulant present in plasma, detected according to the guidelines of the International 
Society on Thrombosis and Haemostasis 
• Anticardiolipin antibody of IgG and/or IgM isotype present in medium to high titre (i.e. more than 
40 GPL or MPL units) as measured by standard ELISA 
• Anti-β2 glycoprotein-1 antibody of IgG and/or IgM isotype in serum or plasma, present in 
medium/high titre (e.g. > 99th centile) 
Clinical Manifestations in the APS criteria 
Vascular Venous/arterial thromboembolic disease 
Neurological Stroke, TIA 
Obstetric Recurrent miscarriage, intrauterine fetal death, stillbirth, early severe pre-
eclampsia, placental insufficiency,  
Non-Criteria Clinical Manifestations of APS 
Cardiovascular Valvular heart disease, Libman-Sachs endocarditis with embolism 
Obstetric HELLP syndrome, intrauterine growth restriction 
Neurological Chorea, dementia, psychiatric disorders, transverse myelopathy, seizures, 
Guillain-Barre syndrome, Sneddon syndrome 
Haematological Autoimmune thrombocytopaenia, autoimmune haemolytic anaemia, 
prolonged aPTT 
Dermatological Livedo reticularis, skin ulceration 
Renal Microthrombotic nephropathy, renal artery stenosis, hypertension 
 
 
Table 2: Criteria and non-criteria clinical manifestations of APS.  
Abbreviations; TIA (transient ischaemic attack); HELLP (haemolysis elevated liver enzymes, 





Figure 1: Pathogenesis of thrombotic and obstetric APS.  
Abbreviations; TLR (toll like receptor), ApoER (Apolipoprotein E receptor), NFkB (nuclear 
factor kappa-light-chain-enhancer of activated B cells), p38MAPK (p38 mitogen-activated 
protein kinases), ICAM-1 (Intercellular Adhesion Molecule 1), VCAM (vascular cell adhesion 
molecule), mTOR (mammalian target of rapamycin), TF (tissue factor), PAR (protease 
activated receptor), VEGF (vascular endothelial growth factor), Ras-ERK (extracellular signal-
regulated kinase), hmw (high molecular weight), aPL (antiphospholipid antibodies), PSGL-1 
(P-selectin glycoprotein ligand 1), NETS (neutrophil extracellular traps), IL (interleukin), 
























Table 3: Summary of investigations for suspected APS.  
Abbreviations; FBC (full blood count), ESR (erythrocyte sedimentation rate), CRP (C reactive 
protein), β2GPI (β2 Glycoprotein I), ANA (Antinuclear antibody), ENA (extractable nuclear 
antigen), C3 (complement C3), dsDNA (double-stranded DNA), ECG (electrocardiogram), CXR 
(Chest radiograph), US (ultrasound), DVT (deep vein thrombosis), CTPA (computerised 
tomography pulmonary angiogram), PE (pulmonary embolism), PS/PT 






• Standard tests 
– FBC 




– Fasting lipids 
– Glucose &Hba1c 
• Urinalysis 
– Urine protein:creatinine ratio 
• Immunology 
– IgG/M Anticardiolipin antibodies 
– IgG/M Anti-β2GPI antibodies 
– Lupus anticoagulant 
– ANA, ENA, C3/C4, dsDNA 
• ± Thrombophilia screen 
– Protein S, Protein C, 




• ± Doppler US (exclude DVT) 
• ± CTPA (exclude PE) 
• ± Brain MRI (exclude stroke) 
• ± Echocardiography (exclude heart 
valve lesions) 
Investigations in APS 
Potential Future Tests (not currently clinically 
validated) 
• Anti PS/PT complex 
• IgA anticardiolipin 
• IgA anti-β2GPI 
• Anti-D1  
Management of APS positive patients Treatment regimen 
Previous VTE not on anticoagulation  Warfarin (Target INR 2-3), or DOAC 
Previous VTE on anticoagulation Warfarin (Target INR 3-4) 
Previous arterial TE not on anticoagulation* Warfarin (Target INR 2-3) + ld aspirin 
OR  
Warfarin (Target INR 3-4) 
Recurrent arterial TE on anticoagulation Warfarin (Target INR 3-4) 
Recurrent thrombosis Ld aspirin or clopidogrel + warfarin 
Management of pregnancy in aPL positive 
women 
Recommendations 
No previous thrombosis + aPL Careful monitoring + ld aspirin 
SLE/APS Ld aspirin + LMWH (+ Hydroxychloroquine) 
Previous thrombosis Ld asprin + LMWH (therapeutic dose) 
Recurrent early miscarriage Ld aspirin + LMWH (prophylaxis dose) 
Late fetal loss/ severe pre-eclampsia/ previous 
IUGR 
Ld aspirin + LMWH  
 
Table 4: Management of APS. 
Abbreviations; VTE (venous thromboembolism), INR (international normalised ratio); DOAC 
(direct oral anticoagulants); ld (low dose); LMWH (low molecular weight heparin); IUGR 
(intrauterine growth retardation); *conflicting expert opinion. 
  
 Potential adjunctive therapies  
Statins Some benefit in recurrent TE despite anticoagulation 
Potential adjunctive therapy 
Eculizumab C5 inhibitor. Case reports of its use in preventing APS-
associated thrombotic microangiopathy post renal 
transplantation, as well as recurrent CAPS. 
Sirolimus Blocks B and T cell activation by inhibiting mTOR. No 
recurrent of APS nephropathy in renal transplants 
receiving sirolimus, and decreased vascular proliferation 
Autologous stem cell transplant Promising early studies in SLE and APS, but high rates of 
adverse events.  
Novel Therapies  in development 
NF-ƙB and p38 MAPK inhibitors Effective in reducing the in vitro pro-inflammatory/pro-
thrombotic effect of APS and reduced TF expression 
Recombinant DI Inhibit development of anti-β2GPI antibodies and inhibits 
aPL mediated pro-thrombotic effects in animal models 
A1-A1 Dimeric inhibitor selectively targets β2GPI in 
β2GPI/antibody complexes, interfering with the in vitro 
interaction with anionic phospholipids and ApoER2.  
 
Table 5: Alternative and future potential therapies and diagnostic assays in APS.  
Abbreviations; aPL (antiphospholipid antibodies), TE (thromboembolism), SLE (systemic 
lupus erythematosus), APS (antiphospholipid syndrome), VTE (venous thromboembolism), 
CAPS (catastrophic antiphospholipid syndrome), β2GPI (β2-glycoprotein I), TF (tissue factor), 
D1 (domain 1), VTE (venous thromboembolism), aCL (anticardiolipin). 
 
  
Key Points  
• APS is an appreciable cause of unprovoked thrombosis and acquired pregnancy 
morbidity 
• Obstetric and thrombotic APS have distinct phenotypes & mechanisms 
• Triple aPL positivity confers the highest risk of clinical events 
• Non-thrombotic manifestations are increasingly recognised 
• Current treatment remains focused on anticoagulation 
• Emerging evidence supports use of DOACs in venous thrombosis & other non-
anticoagulant therapies in refractory APS 
 
